ArticleFrontiers in pharmacology2026
Sex-specific behavioral and monoaminergic network alterations following adolescent binge-like ethanol and WIN55,212-2 exposure under chronic nicotine in rats.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Recreational drug use often begins during adolescence, a critical period of brain maturation characterized by heightened vulnerability to drug-induced neuroplastic changes. Although weekend consumption of alcohol and cannabis and nicotine is commonly perceived as relatively harmless, the long-term neurobiological consequences of such patterns remain poorly understood. Methods: In this study, we investigated the behavioral and neurochemical consequences of combined adolescent exposure to moderate doses of alcohol, cannabinoid receptor agonist WIN55,212-2, and nicotine in male and female Long-Evans rats. From postnatal day (P)30 to P60, animals received daily nicotine (0.3 mg/kg, i.p.) together with intermittent ethanol (3 g/kg, intragastric) and WIN55,212-2 (1.2 mg/kg, i.p.) administered twice weekly, modeling a weekend-like binge pattern of substance use. Behavioral assessments were conducted at baseline (P30), immediately after treatment (P60), and in early adulthood (P90) using the hole-board (HB) and elevated plus maze (EPM) tests. Monoamine levels were subsequently quantified Results: In the HB test, but not in the EPM, treated females exhibited behaviors consistent with increased anxiety-like responses and reduced exploratory drive, including reduced walking and head-dipping, increased grooming, and decreased climbing at P60, with some effects persisting at P90. In contrast, males were minimally affected. Neurochemical analyses revealed only modest changes in absolute serotonin (5-HT) levels in the prefrontal cortex (PFC), with no significant alterations in dopamine (DA) or noradrenaline (NA). However, correlation analyses uncovered a pronounced, sex-dependent reorganization of monoaminergic networks. Females showed increased functional coupling among DA, 5-HT, and NA pathways, particularly involving the PFC and amygdala, whereas males exhibited reduced dopaminergic coherence within the substantia nigra. Discussion: Together, these findings demonstrate that even moderate-low levels of adolescent polydrug exposure can produce long-lasting, sex-specific behavioral alterations, most prominently in females, alongside persistent remodeling of monoaminergic circuitry in both sexes. These results highlight the vulnerability of the adolescent brain to seemingly moderate recreational drug patterns and underscore the importance of considering sex-dependent neurobiological adaptations in assessing long-term neuropsychiatric risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.